• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NALTREXONE Drug Record

  • Summary
  • Interactions
  • Claims
  • NALTREXONE chembl:CHEMBL19019 Approved

    Alternate Names:

    EN-1639A [AS HYDROCHLORIDE]
    TREXAL
    CELUPAN
    VIVITROL
    REVIA
    TREXAN
    EN-1639A
    NALTREXONE
    EN-1639A FREE BASE
    17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
    NALTREXONE HCL
    N-CYCLOPROPYLMETHYL-14-HYDROXYDIHYDROMORPHINONE
    NALTREXON
    17-(CYCLOPROPYLMETHYL)-4,5ALPHA-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
    NALTREXONA
    (-)NALTREXONE
    NALTREXONUM
    17-(CYCLOPROPYLMETHYL)-4,5Α-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
    N-CYCLOPROPYLMETHYLNOROXYMORPHONE
    REVIA®
    chembl:CHEMBL19019
    pubchem.compound:5360515
    chemidplus:16590-41-3
    drugbank:00704
    rxcui:7243

    Drug Info:

    Drug Indications for treatment of substance abuse
    Drug Class Small molecule
    Drug Indications appetite suppressant
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications analgesic
    Year of Approval 1984
    Drug Class opiate antagonists
    (3 More Sources)

    Publications:

    Kato, 2008, [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]., Nihon Arukoru Yakubutsu Igakkai Zasshi
    Herz, 1998, Opioid reward mechanisms: a key role in drug abuse?, Can. J. Physiol. Pharmacol.
    Goodman et al., 2007, Mu opioid receptor antagonists: recent developments., ChemMedChem
    Barrios de Tomasi et al., [Opioid antagonists and alcohol consumption]., Rev Neurol
    Helm et al., Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification., Pain Physician
    Weerts et al., 2008, Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects., Neuropsychopharmacology
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Hendershot CS et al., 2020, OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial., Alcohol Clin Exp Res
    Hartwell EE et al., 2020, Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder., Addiction
    Roche DJO et al., 2019, Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial., Alcohol Alcohol
    Oslin DW et al., 2015, Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial., JAMA Psychiatry
    Foulds JA et al., 2015, OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients., Pharmacogenet Genomics
    Jonas DE et al., 2014, Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis., Pharmacogenomics
    Chamorro AJ et al., 2012, Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis., Addict Biol
    Coller JK et al., 2011, OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence., Pharmacogenet Genomics
    Ray R et al., 2006, Association of OPRM1 A118G variant with the relative reinforcing value of nicotine., Psychopharmacology (Berl)
    Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav
    Herz, 1997, Endogenous opioid systems and alcohol addiction., Psychopharmacology (Berl.)
    Roy et al., 2005, In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance., J. Neurosci.
    Ciampelli et al., 1998, Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus., Horm. Res.
    Wee et al., 2009, Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine., Psychopharmacology (Berl.)
    San-Emeterio et al., 2006, Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice., Neurosci. Lett.
    McCarson et al., 1995, The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration., Neuroscience
  • NALTREXONE   SIGMAR1

    Interaction Score: 3.43

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name MorViva
    Novel drug target Established target
    Trial Name PTI-601

    PMIDs:
    9040115 19484223 18354714


    Sources:
    TdgClinicalTrial

  • NALTREXONE   OPRD1

    Interaction Score: 2.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes
    Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

    PMIDs:
    22954510 9673788 17661275 9040115 17487229 11752352 15788780


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • NALTREXONE   OPRM1

    Interaction Score: 1.49

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

    PMIDs:
    19068776 9673788 17918759 17661275 18354714 17487229 11752352 32020635 31961981 31206155 25760804 25715171 25410894 22515274 21946895 16960700


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • NALTREXONE   DBH

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NALTREXONE   GCG

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9623517


    Sources:
    NCI

  • NALTREXONE   OPRK1

    Interaction Score: 0.91

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist
    Direct Interaction yes
    Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

    PMIDs:
    19484223 9040115 17661275 18354714 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • NALTREXONE   TAC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7536308


    Sources:
    NCI

  • NALTREXONE   BAX

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16716514


    Sources:
    NCI

  • TEND: NALTREXONE

    • Version: 01-August-2011

    Alternate Names:
    NALTREXONE Primary Drug Name

    Drug Info:
    Drug Class opiate antagonists
    Year of Approval 1984

    Publications:

  • TdgClinicalTrial: NALTREXONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: NALTREXONE

    • Version: 14-September-2017

    Alternate Names:
    C679 NCI drug code

    Drug Info:

    Publications:
    San-Emeterio et al., 2006, Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice., Neurosci. Lett.
    McCarson et al., 1995, The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration., Neuroscience
    Ciampelli et al., 1998, Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus., Horm. Res.

  • PharmGKB: naltrexone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav
    Hendershot CS et al., 2020, OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial., Alcohol Clin Exp Res
    Hartwell EE et al., 2020, Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder., Addiction

  • TTD: Naltrexone

    • Version: 2020.06.01

    Alternate Names:
    D0PG8O TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL19019

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL19019

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21